OTC Pharmaceuticals

Akorn develops, manufactures and markets specialty pharmaceuticals, including prescription, consumer health and animal health products. As an industry leader in branded and generic products in alternate dosage forms such as ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays, they focus each day on their mission to improve lives, through the quality, availability and affordability of their products.

Kashiv Specialty is developing a pipeline of treatments for diseases including myasthenia gravis and attention deficit hyperactivity disorder (ADHD). The company plans to use 505(b)(2), an FDA pathway for products that bridge the gap between novel and generic drugs. Products eligible for the pathway include therapies that use a novel drug delivery system to administer an approved molecule.

"This merger with Neos Therapeutics transforms Aytu into a $100 million revenue specialty pharmaceutical company with annualized cost synergies of $15 million anticipated in 2022. With this close, we are in a strong position to enhance our footprint in pediatrics and expand our presence in adjacent specialty care segments. We also are excited to immediately start leveraging RxConnect, a best-in-class patient support program, for our product portfolio of best-in-class prescription therapeutics and consumer health products," said Josh Disbrow, Chief Executive Officer of Aytu BioPharma.